JP2012506051A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012506051A5 JP2012506051A5 JP2011532094A JP2011532094A JP2012506051A5 JP 2012506051 A5 JP2012506051 A5 JP 2012506051A5 JP 2011532094 A JP2011532094 A JP 2011532094A JP 2011532094 A JP2011532094 A JP 2011532094A JP 2012506051 A5 JP2012506051 A5 JP 2012506051A5
- Authority
- JP
- Japan
- Prior art keywords
- lipoprotein
- insulin resistance
- parameters
- risk
- score
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004895 Lipoproteins Human genes 0.000 claims 29
- 108090001030 Lipoproteins Proteins 0.000 claims 28
- 206010022489 Insulin Resistance Diseases 0.000 claims 26
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 22
- 239000002245 particle Substances 0.000 claims 13
- 238000005259 measurement Methods 0.000 claims 11
- 239000000523 sample Substances 0.000 claims 10
- 238000005481 NMR spectroscopy Methods 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 210000002966 serum Anatomy 0.000 claims 5
- 239000012472 biological sample Substances 0.000 claims 4
- 238000004590 computer program Methods 0.000 claims 3
- 235000020925 non fasting Nutrition 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000004891 communication Methods 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10683308P | 2008-10-20 | 2008-10-20 | |
| US61/106,833 | 2008-10-20 | ||
| PCT/US2009/005689 WO2010047767A2 (en) | 2008-10-20 | 2009-10-20 | Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012506051A JP2012506051A (ja) | 2012-03-08 |
| JP2012506051A5 true JP2012506051A5 (https=) | 2012-12-06 |
| JP5393798B2 JP5393798B2 (ja) | 2014-01-22 |
Family
ID=42109358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011532094A Active JP5393798B2 (ja) | 2008-10-20 | 2009-10-20 | リポタンパク質インスリン抵抗性指数、ならびに同一物を生成するための関連する方法、システムおよびコンピュータプログラム |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8386187B2 (https=) |
| EP (2) | EP2344890B1 (https=) |
| JP (1) | JP5393798B2 (https=) |
| KR (1) | KR20110086074A (https=) |
| AU (1) | AU2009308124B2 (https=) |
| CA (1) | CA2741034C (https=) |
| WO (1) | WO2010047767A2 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110086074A (ko) | 2008-10-20 | 2011-07-27 | 리포사이언스, 인크. | 지질단백질 인슐린 저항성 지표 및 이와 관련된 방법, 시스템 및 이를 생성하기 위한 컴퓨터 프로그램 |
| SG10201608139VA (en) * | 2011-06-30 | 2016-11-29 | Liposcience Inc | Quantitative nmr clinical analyzers with automatic nmr temperature sensitivity compensation that accommodate large ambient operational temperature ranges |
| TWI596494B (zh) | 2012-03-05 | 2017-08-21 | Ｏｐｋｏ診斷法有限責任公司 | 預測前列腺癌風險及前列腺腺體體積之方法及裝置 |
| US9483612B2 (en) | 2012-04-27 | 2016-11-01 | Liposcience, Inc. | CHD risk stratification evaluations for subjects with high levels of large HDL-P |
| US9361429B2 (en) * | 2012-06-08 | 2016-06-07 | Liposcience, Inc. | Multi-parameter diabetes risk evaluations |
| US9928345B2 (en) | 2012-06-08 | 2018-03-27 | Liposciences, Inc. | Multiple-marker risk parameters predictive of conversion to diabetes |
| US9470771B2 (en) | 2012-06-08 | 2016-10-18 | Liposcience, Inc. | NMR measurements of NMR biomarker GlycA |
| US9551768B2 (en) | 2013-03-15 | 2017-01-24 | East Carolina University | NMR method for monitoring changes in the core of lipoprotein particles in metabolism and disease |
| CA2931648C (en) * | 2014-01-06 | 2022-11-29 | Liposcience, Inc. | Multiple-marker risk parameters predictive of conversion to diabetes |
| KR102505543B1 (ko) | 2014-03-28 | 2023-03-02 | 옵코 다이어그노스틱스, 엘엘씨 | 전립선암 진단에 관한 조성물 및 방법 |
| US12326453B2 (en) | 2014-03-28 | 2025-06-10 | Opko Diagnostics, Llc | Compositions and methods for active surveillance of prostate cancer |
| US9952232B2 (en) | 2014-09-11 | 2018-04-24 | Liposcience, Inc. | Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameter |
| WO2016123163A2 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
| PT3253800T (pt) | 2015-03-27 | 2021-04-28 | Opko Diagnostics Llc | Padrões de antigénio da próstata e suas utilizações |
| KR102539142B1 (ko) | 2016-09-05 | 2023-06-01 | 삼성전자주식회사 | 스펙트럼 분석 장치와 방법, 및 혈당 측정 장치 |
| US10775458B2 (en) | 2018-03-05 | 2020-09-15 | Texas Tech University System | Method and system for non-invasive measurement of metabolic health |
| US12289368B2 (en) * | 2020-10-29 | 2025-04-29 | Telefonaktiebolaget Lm Ericsson (Publ) | Checking state consistency in a log replication configuration |
| CN113117241B (zh) * | 2021-04-15 | 2022-01-28 | 中国科学院合肥物质科学研究院 | 一种提高胰岛素水平和敏感性的磁场发生装置及其应用 |
| CN115188493A (zh) * | 2022-07-13 | 2022-10-14 | 天津市人民医院 | 一种胰岛素抵抗预测模型的构建系统、方法及应用 |
| WO2024097429A1 (en) * | 2022-11-05 | 2024-05-10 | Texas Tech University System | Methods and tools for assessing cardiometabolic health and hidden disease risk among apparently healthy individuals |
| CN120613144B (zh) * | 2025-05-27 | 2026-02-03 | 中国科学院精密测量科学与技术创新研究院 | 一种基于血液nmr编辑谱的药物敏感度预测方法 |
| CN120280166A (zh) * | 2025-06-10 | 2025-07-08 | 南昌大学第二附属医院 | 术后胰岛素抵抗风险预测模型的构建方法及系统 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4933844A (en) | 1988-09-26 | 1990-06-12 | Otvos James D | Measurement of blood lipoprotein constituents by analysis of data acquired from an NMR spectrometer |
| WO1993003450A1 (en) | 1991-07-30 | 1993-02-18 | North Carolina State University | Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy |
| US6653140B2 (en) * | 1999-02-26 | 2003-11-25 | Liposcience, Inc. | Methods for providing personalized lipoprotein-based risk assessments |
| EP1171778B1 (en) * | 1999-04-22 | 2006-03-01 | Liposcience, Inc. | Nmr-method for determining the risk of developing type 2 diabetes |
| US7395158B2 (en) * | 2000-05-30 | 2008-07-01 | Sensys Medical, Inc. | Method of screening for disorders of glucose metabolism |
| US6890905B2 (en) * | 2001-04-02 | 2005-05-10 | Prosidion Limited | Methods for improving islet signaling in diabetes mellitus and for its prevention |
| WO2003012416A1 (en) * | 2001-08-01 | 2003-02-13 | Liposcience, Inc. | Method of determining presence and concentration of lipoprotein x in blood plasma and serum |
| CA2467420A1 (en) * | 2001-11-13 | 2003-05-22 | The Regents Of The University Of California | Ion mobility analysis of biological particles |
| WO2004040407A2 (en) | 2002-10-25 | 2004-05-13 | Liposcience, Inc. | Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals |
| DE10315877B4 (de) * | 2003-04-08 | 2005-11-17 | Roche Diagnostics Gmbh | Krankheitsverlaufkontrolle |
| FR2853911B1 (fr) * | 2003-04-17 | 2005-07-08 | Merck Sante Sas | Gene induit par l'insuline, comme cible therapeutique dans le diabete |
| ES2556164T3 (es) * | 2003-09-23 | 2016-01-13 | The General Hospital Corporation | Cribado de la preeclampsia |
| WO2005098463A2 (en) * | 2004-04-01 | 2005-10-20 | Liposcience, Inc. | Nmr clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation of biosamples |
| ES2571929T3 (es) * | 2004-05-26 | 2016-05-27 | Region Nordjylland | Procedimiento para determinar la cantidad de CD36 circulante |
| DE102004026903B4 (de) * | 2004-06-01 | 2006-05-18 | Universität Regensburg | Verfahren zur Bestimmung von Lipoproteinen in Körperflüssigkeiten und Messanordnung dafür |
| WO2006014678A2 (en) * | 2004-07-20 | 2006-02-09 | Genentech, Inc. | Compositions and methods of using angiopoietin-like 4 protein |
| JP4210855B2 (ja) * | 2004-09-28 | 2009-01-21 | 大塚製薬株式会社 | インスリン抵抗性の評価方法 |
| US7323296B2 (en) * | 2004-10-01 | 2008-01-29 | Yuanhong Ma | Method and index for diagnosing insulin resistance |
| EP1645877A1 (en) * | 2004-10-08 | 2006-04-12 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | Method for providing a insulin resistance biomarker profile of one or more lipids |
| WO2006110082A1 (en) * | 2005-04-11 | 2006-10-19 | Astrazeneca Ab | A method and a kit for diagnosing type 2 diabetes, metabolic syndrome, sub clinical atherosclerosis, myocardial infarct, stroke or clinical manifestations of diabetes. |
| WO2007133593A2 (en) * | 2006-05-10 | 2007-11-22 | Liposcience, Inc. | Methods, systems and computer programs for assessing chd risk using weighted hdl particle number measurements |
| MX2010000414A (es) * | 2007-07-17 | 2010-04-01 | Metabolon Inc | Biomarcadores para prediabetes, enfermedades cardiovasculares y otros trastornos relacionados con sindrome metabolico, y metodos de uso de los mismos. |
| US20090191576A1 (en) * | 2008-01-28 | 2009-07-30 | Yuanhong Ma | Method and index for diagnosing insulin resistance |
| KR20110086074A (ko) | 2008-10-20 | 2011-07-27 | 리포사이언스, 인크. | 지질단백질 인슐린 저항성 지표 및 이와 관련된 방법, 시스템 및 이를 생성하기 위한 컴퓨터 프로그램 |
-
2009
- 2009-10-20 KR KR1020117011307A patent/KR20110086074A/ko not_active Ceased
- 2009-10-20 WO PCT/US2009/005689 patent/WO2010047767A2/en not_active Ceased
- 2009-10-20 EP EP09822305.0A patent/EP2344890B1/en active Active
- 2009-10-20 AU AU2009308124A patent/AU2009308124B2/en not_active Expired - Fee Related
- 2009-10-20 US US12/582,259 patent/US8386187B2/en active Active
- 2009-10-20 JP JP2011532094A patent/JP5393798B2/ja active Active
- 2009-10-20 EP EP21190653.2A patent/EP4016105A1/en not_active Ceased
- 2009-10-20 CA CA2741034A patent/CA2741034C/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012506051A5 (https=) | ||
| Voulgaridou et al. | Diagnostic criteria and measurement techniques of sarcopenia: a critical evaluation of the up-to-date evidence | |
| Cerezuela-Espejo et al. | Are we ready to measure running power? Repeatability and concurrent validity of five commercial technologies | |
| Crotty et al. | Reliability and validity of the lactate pro 2 analyzer | |
| JP2015522806A5 (https=) | ||
| Merry et al. | The validity and reliability of two commercially available load sensors for clinical strength assessment | |
| Wang et al. | Characterization of human plasma proteome dynamics using deuterium oxide | |
| De Simone et al. | Allometric normalization of cardiac measures: producing better, but imperfect, accuracy | |
| JP2012515898A5 (https=) | ||
| Liu et al. | Adult obesity diagnostic tool: a narrative review | |
| Araujo-Moura et al. | Blood pressure measurement in pediatric population: comparison between automated oscillometric devices and mercury sphygmomanometers—a systematic review and meta-analysis | |
| Held et al. | Reliability of the maximal lactate accumulation rate in rowers | |
| Rodrigues Filho et al. | Evaluating the impact of measurement uncertainty in blood pressure measurement on hypertension diagnosis | |
| JP5199685B2 (ja) | 健康診断の検査値換算プログラム | |
| JP2025066131A (ja) | マルチパラメータ代謝脆弱性指数評価 | |
| Cuspidi et al. | Early left ventricular dysfunction and non-dipping: when ejection fraction is not enough. A meta-analysis of speckle tracking echocardiography studies | |
| Knight et al. | Epidemiologic monitoring of prenatal screening for neural tube defects and Down syndrome | |
| TW201516725A (zh) | 單一核苷酸多型性疾病發生率預測系統 | |
| Eriksen et al. | A maximal cycle test with good validity and high repeatability in adults of all ages | |
| JP2009050596A (ja) | 腹囲推定装置 | |
| US8380297B2 (en) | System for measuring a user's percentage of body fat | |
| Xu et al. | Establishment of hypertension risk nomograms based on physical fitness parameters for men and women: a cross-sectional study | |
| JPWO2016103390A1 (ja) | インスリン分泌能分析装置、当該装置を備えるインスリン分泌能分析システム及びインスリン分泌能分析方法 | |
| Vázquez-Rodríguez et al. | Concordance between automatic and manual recording of blood pressure depending on the absence or presence of atrial fibrillation | |
| Tang et al. | Metabolite Fusion between Breath and Blood Enables More In-Depth Understanding of the Endogenous Metabolome |